ReviewFrontiers in medicine2026
The economic value of mismatch repair-guided immunotherapy in endometrial cancer: companion testing and patient selection.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mismatch repair (MMR) status has moved from hereditary-cancer screening to a central predictive biomarker for immunotherapy in endometrial cancer. The marked difference in treatment benefit between MMR-deficient/microsatellite instability-high (dMMR/MSI-H) and MMR-proficient/microsatellite-stable (pMMR/MSS) tumors creates an economic rationale for companion testing, but the value of testing depends on assay accuracy, treatment price, duration, survival extrapolation, and local willingness-to-pay thresholds. This Mini Review examines the clinical and economic value of MMR-guided immunotherapy in advanced and recurrent endometrial cancer. A targeted literature search of PubMed/MEDLINE, Embase, Web of Science, and the Cochrane Library from database inception through 31 July 2026. We summarize practical testing pathways based on four-protein immunohistochemistry, reflex mutL homolog 1 (MLH1) promoter methylation, MSI assays, and selective next-generation sequencing; review MMR-stratified evidence from major immunotherapy trials; and compare published cost-effectiveness analyses of pembrolizumab, dostarlimab, atezolizumab, durvalumab-based regimens, and pembrolizumab plus lenvatinib. Across studies, dMMR/MSI-H disease generally generates the largest quality-adjusted survival gains and the most favorable incremental cost-effectiveness ratios, whereas the economic case in pMMR/MSS disease is more sensitive to drug pricing and modeling assumptions. Overall, MMR testing can function as an allocation technology that prioritizes high-value treatment, while future work should harmonize testing, manage discordant results, refine biomarkers for pMMR tumors, and incorporate long-term survival, quality of life, equity, and value of information into economic models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.